Reference

Compare peptides

Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.

Compound 1

Compound 2

Compound 3 (optional)

Compound 4 (optional)

No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.

Link to this comparison: /compare?peptides=thymosin-beta-4,bpc-157,tb-500

Side-by-side comparison of Thymosin beta-4, BPC-157, TB-500
Identity
	Thymosin beta-4	BPC-157	TB-500
Class	43-residue N-terminally acetylated peptide; the parent molecule of the TB-500 fragment	Synthetic 15-residue peptide corresponding to a partial sequence of human gastric juice protein BPC	Synthetic acetylated heptapeptide corresponding to the actin-binding region of thymosin beta-4 (residues 17–23)
Also listed as	Timbetasin, Thymosin β4, Tβ4	Pentadecapeptide BPC 157, PL-14736, Bepecin	Thymosin beta-4 fragment (LKKTETQ), Ac-LKKTETQ-OH, TB500
Molecular formula	C212H350N56O78S	C62H98N16O22	C38H68N10O14
Molecular weight	4963 g/mol	1419.5 g/mol	889.0 g/mol
CAS	77591-33-4	137525-51-0	885340-08-9
PubChem CID	16132341	9941957	62707662
Sequence length	43 residues	15 residues	7 residues
Data caveat	Much of the wound-healing literature cited in commercial TB-500 material concerns this full-length peptide. Full caveat	None recorded	TB-500 is commonly described in vendor material as the Ac-SDKP fragment. Full caveat
United States regulatory status
Status	No FDA-approved product	No FDA-approved product	No FDA-approved product
FDA application	None recorded	None recorded	None recorded
Compounding	No FDA compounding entry recorded	FDA bulk-substance nomination withdrawn; safety concerns remain published.	FDA bulk-substance nomination withdrawn; safety concerns remain published.
WADA	Named at S2.3 — “Thymosin-β4 and its derivatives e.g. TB-500”, among growth factors and growth factor modulators. Prohibited at all times.	Named in Class S0 (Non-Approved Substances). Prohibited at all times; Specified Substance.	Named at S2.3 — “Thymosin-β4 and its derivatives e.g. TB-500”. Prohibited at all times; non-Specified.
Research profile
Research purpose	No plain-English profile recorded	Preclinical soft-tissue and gut repair	Preclinical actin-binding fragment research
Proposed mechanism	No plain-English profile recorded	Proposed to promote angiogenesis and cell migration through VEGF upregulation and focal-adhesion signalling. Most of the mechanistic work comes from a small number of laboratory groups.	Corresponds to the actin-binding region of thymosin beta-4. The proposed mechanism is actin cytoskeletal regulation and cell migration; direct human evidence for the fragment is very limited.
Human evidence	No plain-English profile recorded	Predominantly animal and cell data, plus one small retrospective human case series. Therapept indexes no completed randomised Phase 3 trial.	Most wound-healing human data concern full-length thymosin beta-4, a different molecule. Therapept indexes no human interventional trial of the TB-500 fragment itself.
Evidence tier	No plain-English profile recorded	Preclinical models; no human efficacy trial indexed	Preclinical models; no human efficacy trial indexed
Known safety concerns	No plain-English profile recorded	No approved product; FDA published immunogenicity, impurity and characterisation concerns. Named in WADA Class S0 (non-approved substances); prohibited at all times. Human safety data are too limited to characterise a risk profile.	No approved product; FDA published aggregation and immunogenicity concerns and stated it had not identified human exposure data for the fragment. Named on the WADA Prohibited List at S2.3 as a thymosin-beta-4 derivative. Human safety of the fragment is essentially uncharacterised.
Evidence gaps	No plain-English profile recorded	Independent replication outside the originating laboratory network. Any randomised human trial with clinical endpoints. Oral bioavailability and the fate of the peptide after administration.	Any human interventional data for the fragment. Whether the actin-binding fragment reproduces the parent protein's effects. Long-term safety.
Head-to-head evidence	No plain-English profile recorded	No published head-to-head human trial against TB-500 or any other repair peptide.	No published head-to-head trial against BPC-157 or full-length thymosin beta-4.
Named pathways	No plain-English profile recorded	VEGF signalling · Angiogenesis · Focal adhesion kinase · Fibroblast migration	Actin cytoskeleton · Cell migration · Thymosin beta-4 biology
Evidence on file
Records	0Open evidence file	9Open evidence file	6Open evidence file
Human-interventional records	0	0	0
Human-observational records	0	1	0
Animal records	0	1	1
In-vitro records	0	1	0
Reviews	0	3	2
Regulatory documents	0	3	3
Earliest indexed	Not recorded	2003	1999
Latest indexed	Not recorded	2026	2026

Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.